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ABSTRACT
Cannabinoid receptors (CB) are expressed throughout human skin epithelium. CB1
activation inhibits human hair growth and decreases proliferation of epidermal ker-
atinocytes.Sincepsoriasisisachronichyperproliferative,inﬂammatoryskindisease,
it is conceivable that the therapeutic modulation of CB signaling, which can inhibit
both proliferation and inﬂammation, could win a place in future psoriasis manage-
ment. Given that psoriasis is characterized by up-regulation of keratins K6 and K16,
we have investigated whether CB1 stimulation modulates their expression in human
epidermis. Treatment of organ-cultured human skin with the CB1-speciﬁc agonist,
arachidonoyl-chloro-ethanolamide(ACEA),decreasedK6andK16stainingintensity
in situ.Atthegeneandproteinlevels,ACEAalsodecreasedK6expressionofcultured
HaCaTkeratinocytes,whichshowsomesimilaritiestopsoriatickeratinocytes.These
eVects were partly antagonized by the CB1-speciﬁc antagonist, AM251. While CB1-
mediated signaling also signiﬁcantly inhibited human epidermal keratinocyte pro-
liferation in situ, as shown by K6/Ki-67-double immunoﬂuorescence, the inhibitory
eVect of ACEA on K6 expression in situ was independent of its anti-proliferative
eVect.GivenrecentappreciationoftheroleofK6asafunctionallyimportantprotein
that regulates epithelial wound healing in mice, it is conceivable that the novel CB1-
mediated regulation of keratin 6/16 revealed here also is relevant to wound healing.
Takentogether,ourresultssuggestthatcannabinoidsandtheirreceptorsconstitutea
novel,clinicallyrelevantcontrolelementofhumanK6andK16expression.
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Endocannabinoidsaswellasexocannabinoids(suchastheactivecomponentsofcannabis)
control the function of various types of cells via cannabinoid receptor (CB)-dependent
or independent manner (Kupczyk, Reich & Szepietowski, 2009). The endocannabinoid
system (ECS) consists of these CBs, their endogenous ligands (i.e. endocannabinoids,
such as anandamide [AEA] and 2-arachidonoylglycerol), and enzymes responsible for
endocannabinoid synthesis and degradation (Biro et al., 2009). In human skin, many
diVerent types of cellsare now known to express functional CBs (Biro et al., 2009;Czifra et
al., 2012; Pucci et al., 2012; Roelandt et al., 2012; Stander et al., 2005; Sugawara et al., 2012;
Telek et al., 2007; Toth et al., 2011). The ECS is increasingly appreciated as an important
regulator of skin function in health and disease. For example, the ECS has become
implicated in pain (Khasabova et al., 2012; Walker & Hohmann, 2005) and itch control
(Stander,Reinhardt&Luger,2006),andthemodulationofinﬂammation(Klein,2005)and
allergy(Karsaketal., 2007).Inaddition, CB1signalingisimportantin mastcellactivation
andintracutaneousmastcellmaturationfromresidentprogenitors(Sugawaraetal.,2012).
Furthermore, it regulates ﬁbrosis (Akhmetshina et al., 2009), sebocyte diVerentiation
(Dobrosi et al., 2008) and eccrine epithelial biology (Czifra et al., 2012). Nevertheless,
the functions of CB-mediated signaling in human keratinocytes (KCs) in situ are as yet
poorlyunderstood.
We have previously shown that outer root sheath KCs of human hair follicles (HFs)
express CB1. CB1 stimulation by the endocannabinoid, AEA, markedly inhibited human
HFgrowthbyinhibitinghairmatrixKCproliferationandinducingapoptosis,thusleading
toprematureHFinvolution(catagendevelopment).ThiswasreversedbytheCB1-speciﬁc
antagonist, AM251 (Telek et al., 2007). Similarly, human epidermal KC express CBs, and
theirdiVerentiationisregulatedviaCB1(Maccarroneetal.,2003;Paradisietal.,2008).AEA
also markedly suppresses human epidermal KC proliferation and induces apoptosis via
CB1in vitroandin situ(Tothetal.,2011).ThissuggeststhattheECScouldbecomeauseful
therapeutic target in the management of chronic hyperproliferative human skin diseases,
suchaspsoriasis(Tothetal.,2011).
However, it remains unclear whether and how CB1-mediated signaling impacts on
human KC diVerentiation, namely on the expression of hyperproliferation-associated
keratins. Psoriasis is characterized by the upregulation of keratins K6 and K16 expression
within lesional epidermis (Korver et al., 2006; Mommers et al., 2000). This pair of keratins
isalsoprominentlyup-regulatedintheepidermisunderwoundhealingconditionsinmen
and mice (Moll, Divo & Langbein, 2008; Paladini et al., 1996; Rotty & Coulombe, 2012)
and is constitutively expressed in the outer root sheath KCs of human HFs (Langbein &
Schweizer, 2005; Moll, Divo & Langbein, 2008; Ramot et al., 2009). Psoriasis is a chronic
inﬂammatory, hyperproliferative dermatosis that, in addition to its anti-proliferative
properties (Telek et al., 2007; Van Dross et al., 2012), might also proﬁt from the
well-recognized anti-inﬂammatory properties of CB1-mediated signaling (Sugawara et
al., 2012; Wilkinson & Williamson, 2007). Therefore, we have investigated whether CB1
stimulation modulates K6 and K16 expression in human skin. This question was made
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onlyawoundhealing-associatedkeratin,butactivelydown-regulatesKCmigrationduring
woundrepair(Rotty&Coulombe,2012).
In order to answer this question, we used the CB1-speciﬁc agonist, arachidonoyl-
chloro-ethanolamide(ACEA)(Harveyetal.,2012),andcheckeditseVectonK6expression
in situ. This was done by utilizing full thickness human skin organ culture (Lu et al., 2007)
as a physiologically and clinically relevant model to study multiple aspects of human
skin biology under clinically relevant conditions in vitro (Bodo et al., 2010; Knuever et al.,
2012; Langan et al., 2010; Lu et al., 2007; Sugawara et al., 2012). In order to conﬁrm the
CB1-speciﬁcity of the observed eVects of ACEA, we also used the CB1-speciﬁc antagonist,
AM251(Chandaetal.,2011).
K16 serves as the type I keratin partner of K6 in the formation of intermediate
ﬁlament heterodimers (Moll, Divo & Langbein, 2008). It is also involved in epidermal
barrier function (Grzanka et al., 2012; Thakoersing et al., 2012), and is up-regulated in
hyperprolifeative conditions of the skin such as psoriasis (Iizuka et al., 2004) and atopic
dermatitis (Grzanka et al., 2012). Therefore, we also examined the eVects of ACEA on K16
expression.
HaCaT cells are a highly proliferating human KC line known to overexpress K6
(Ryle et al., 1989). Since HaCaT KCs share some other characteristics with psoriatic
KCs and are often employed as surrogate “psoriatic” KCs (Balato et al., 2012; Farkas
et al., 2001; George et al., 2010; Kim et al., 2011; Ronpirin & Tencomnao, 2012; Saelee,
Thongrakard & Tencomnao, 2011), we also tested whether and how ACEA modulated
K6 expression in these cells in vitro. In order to delineate whether any such eVects
on keratin expression resulted only indirectly from a possible down-regulation of KC
proliferation by CB1 stimulation (Toth et al., 2011), double-labeling and quantitative
immunohistomorphometry for both K6 and Ki-67 was performed. Finally, to investigate
whether K6-expressing human KCs co-express CB1, double-immunolabeling for both
antigenswasemployed.
MATERIALS AND METHODS
Human skin organ culture
Isolated human skin samples obtained from elective plastic surgery procedures (32 pieces
of skin fragments obtained by 4 mm punch biopsies from 4 individuals; 3 females and
a male aged 26–74, average: 56.5; 3 skin samples were taken from the scalp and one
was taken from the hip) were maintained in supplemented serum-free William’s E
medium as previously reported (Bodo et al., 2010; Knuever et al., 2012; Lu et al., 2007;
Poeggeler et al., 2010). Human tissue collection and handling was performed according
to Helsinki guidelines, after institutional review board ethics approval (University of
Luebeck)andinformedpatientconsent.
Skin samples were ﬁrst incubated overnight to adapt to culture conditions after
which the medium was replaced and vehicle or test substances were added. For human
skin organ culture, skin samples were treated with ACEA (Sigma-Aldrich, Taufkirchen,
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1-day after the overnight incubation (Sugawara et al., 2012). Following culturing for
the time indicated, skin samples were cryoembedded and prepared for histology, im-
munohistochemistry/immunoﬂuorescence and quantitative immunohistomorphometry
(Ramot et al., 2010; Ramot et al., 2011; Sugawara et al., 2012). Each evaluation was
performed on 2–4 sections of 2 skin fragments per each treatment group from 2–4
individuals.
Cell culture
Human immortalized HaCaT KCs (Boukamp et al., 1988) were cultured in DMEM
(Sigma-Aldrich)supplementedwith10%fetalbovineserum(Invitrogen,Paisley,UK)and
antibiotics (PAA Laboratories, Pasching, Austria). For qRT-PCR, the cells were cultured
withACEA(1M)for8h.
qRT-PCR
qRT-PCR was performed on an ABI Prism 7000 sequence detection system (Applied
Biosystems/LifeTechnologies,FosterCity,CA,USA)usingthe5’nucleaseassayasdetailed
in our previous reports (Toth et al., 2011; Toth et al., 2009). Total RNA was isolated from
HaCaTkeratinocytesusingTRIreagent(AppliedBiosystems/LifeTechnologies,FosterCity,
CA, USA) and digested with recombinant RNase-free DNase-1 (Applied Biosystems)
according to the manufacturer’s protocol. After isolation, one g of total RNA was
reverse-transcribed into cDNA by using High Capacity cDNA kit (Applied Biosystems)
followingthemanufacturer’sprotocol.PCRampliﬁcationwasperformedbyusingspeciﬁc
TaqMan primer and probes (Applied Biosystems, assay ID: Hs01699178 g1 for human
K6A). As internal housekeeping gene control, transcripts of cyclophillin A (PPIA) were
determined(AssayID:Hs99999904forhumanPPIA).TheamountoftheK6Atranscripts
wasnormalizedtothecontrolgeneusingthe1CTmethod.
Immunohistochemistry
For the detection of K6 in organ cultured human skin as well as cultured HaCaT KCs,
indirect immunoﬂuorescence staining was performed using mouse anti-human K6
antibody (Progen, Ks6.KA12) at 1:10 dilution as a primary antibody and rhodamine
conjugatedgoatanti-mouseIgG(JacksonImmunoresearchLaboratories,WestGrove,PA)
at1:200dilutioninphosphate-buVeredsaline(PBS)asasecondaryantibody.
To study the proliferation of epidermal KCs, double-immunostaining for K6 and Ki-67
was performed. Brieﬂy, after the staining for K6 with FITC conjugated goat anti-mouse
IgG (Jackson Immunoresearch Laboratories) as a secondary antibody, sections were
incubated overnight at 4 C with a mouse anti-human Ki-67 antibody (DAKO, Hamburg,
Germany) at 1:20 in PBS. Sections were then washed with PBS, followed by incubation
withrhodamineconjugatedgoatanti-mouseIgG(JacksonImmunoresearchLaboratories)
(1:200inPBS,45min)atroomtemperature.
To investigate the localization of CB1 and K6, double immunostaining was performed.
For CB1 immunostaining, the highly sensitive tyramide signal ampliﬁcation (TSA)
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overnight at 4 C with rabbit anti-CB1 (Santa Cruz, CA, USA) at 1:400 diluted in TNB
(Tris, NaOH, Blocking reagent, TSA kit; Perkin-Elmer). Thereafter, the samples were
labeled with goat biotinylated antibody against rabbit IgG (Jackson Immunoresearch
Laboratories) at 1:200 in TNB for 45 min at room temperature. Sections were then
stained with streptavidin-conjugated horseradish peroxidase (1:100, 30 min, TSA kit)
andwere ﬁnallyincubated withrhodamine conjugated tyramide(1:50, TSAkit). TheTSA
method was applied according to the manufacturer’s protocol. For the second primary
labeling, mouse anti-human K6 antibody (Progen) was applied at 1:20 in PBS, overnight
at 4 C. After the wash with PBS, the sections were incubated with FITC conjugated goat
anti-mouse IgG (Jackson Immunoresearch Laboratories) (1:200 in PBS, 45 min) at room
temperature.
For K16 antigen detection, we used the LSAB (DCS, Germany) detection method
(Ramot et al., 2009) using the K16-gp as primary antibody (guinea-pig, PROGEN,
Heidelberg, Germany, dilution 1:1000, GP-CK16), and biotinylated goat anti-guinea
pig as secondary antibody (Vector Laboratories, Burlingame, CA, USA, dilution 1:200).
HistoGreen(Linaris,Wertheim-Bettingen,Germany)wasusedasperoxidasesubstrate.
For all immunostainings, the respective primary antibodies were omitted as negative
controls, and morphological criteria and reproduction of the previously published
intracutaneous expression patterns of the examined antigens were used as internal
positive and negative controls (Moll, Divo & Langbein, 2008). For all experiments, control
and treated sections were stained (and later evaluated) on the same day by the same
investigator.Toavoidstainingbiases,wecalculatedtherelativestainingintensity(arbitrary
intensity;1ascontrolgroup)amongtreatmentgroupspereachindividualandthenpooled
datafromalloftheexperiments.
High magniﬁcation images of K6/Ki67 double immunoﬂuorescence and K6 im-
munoﬂuorescence on HaCaT cells were taken by laser scanning confocal microscopy
(Fluoview300,OlympusTokyo,Japan)runningFluoview2.1software(Olympus).
The staining intensity of K6 and K16 in deﬁned reference areas was assessed by
quantitative immunohistomorphometry using the ImageJ software (NIH: National
Institutes of Health, Bethesda, MD) (Bodo et al., 2010; Ramot et al., 2010; Ramot et al.,
2011). For epidermal evaluation, staining intensity was evaluated in the suprabasal cells,
and for HaCaT cells, staining intensity was measured in the colonies formed. For K6
immunoﬂuorescence intensity, skin sections from 4 diVerent individuals were used, while
K16 immunoﬂuorescence intensity and %Ki67 were evaluated in skin sections from 2
patients. 4–6 sections per one individual (2 sections per investigated skin fragment) were
used for each evaluation. Each section was evaluated in two/three diVerent non-adjacent
microscopic ﬁelds (200), and the mean intensity was measured, and considered as a
value. Each treatment group was compared to the control group (average value), and
relative change in expression was calculated. Highly comparable results were obtained
fromdiVerentsectionsfromdiVerentindividuals.
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Signiﬁcance of diVerence between two groups was evaluated using Student’s t-test for
unpaired samples. For multiple comparisons, one-way analysis of variance (ANOVA)
was used, followed by Bonferroni’s multiple comparison test, using Prism 5.0 software
(GraphPad Prism Program, GraphPad, San Diego, CA). p values <0.05 were regarded as
signiﬁcant. All data in the ﬁgures are expressed as mean C SEM. *p < 0:05, **p < 0:01,
***p < 0:001fortheindicatedcomparisons.
RESULTS AND DISCUSSION
The CB1-selective agonist, ACEA, down-regulates K6 protein
expression in situ
First, we asked whether the CB1-speciﬁc synthetic agonist ACEA (Pertwee et al., 2010;
Sugawara et al., 2012) can modulate the expression of keratin K6 in human skin. K6
staining intensity within the epidermis of full-thickness human skin that had been
organ-cultured for 24 h under serum-free conditions in the presence of ACEA (30 M)
orvehiclealonewasassessedbyquantitativeimmunohistomorphometry.Thisshowedthat
K6 immunoreactivity (IR) was signiﬁcantly reduced after ACEA treatment, compared to
thevehiclecontrolgroup(Figs.1Aand1B).
This down-regulation was abrogated in part by the co-administration with the
CB1-speciﬁc antagonist, AM251 (Pertwee et al., 2010; Sugawara et al., 2012) (Figs. 1A
and 1B). Therefore, intraepidermal K6 protein expression in normal human skin in situ is
down-regulatedinaCB1-speciﬁcmanner.
ACEA also down-regulates K16 protein expression in situ
Since K16 is the type I keratin partner of K6 in KCs and is thought to stabilize this keratin
protein as a cytoskeletal heteropolymeric intermediate ﬁlament (Ramot et al., 2009), we
next analyzed K16 IR in the epidermis of organ cultured human skin samples treated with
ACEA.InlinewiththeK6proteinexpression,K16IRwasalsosigniﬁcantlydown-regulated
byACEAin situ(Figs.1Cand1D).
CB1-mediated signaling also regulates K6 expression in cultured,
hyperproliferative human keratinocytes
In order to check whether the observed CB1-mediated eVects on K6 regulation within
intact human skin epithelium depend on intact epithelial-mesenchymal interactions
between epidermis and dermis, or are likely to reﬂect a direct impact of CB1 ligands on
epidermal keratinocytes, we next investigated K6 expression in cultured human HaCaT
KCs. This transformed human KC line is well-appreciated to constitutively express K6
and to be hyperproliferative (just like human wounded and psoriatic KC) (Balato et al.,
2012; Farkas et al., 2001; George et al., 2010; Kim et al., 2011; Ronpirin & Tencomnao,
2012; Ryle et al., 1989; Saelee, Thongrakard & Tencomnao, 2011). K6 is expressed in hyper-
proliferative cells (Weiss, Eichner & Sun, 1984) and both K6 expression and basal layer
epidermal KC proliferation are increased in psoriasis lesions (Donetti et al., 2012; GriYths
&Barker,2007;Korveretal.,2006;Litvinovetal.,2011;Mommersetal.,2000).HaCaTcells
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 6/18Figure1 TheCB1speciﬁcagonist,ACEAsigniﬁcantlyinhibitsK6andK16expressioninsitu.(A)Rep-
resentative images of K6 immunoﬂuorescence with organ cultured human skin treated with
ACEA/AM251 (1-day). (B) Statistical analysis of K6 immunoﬂuorescence intensity in organ cultured
human skin (quantitative immunohistomorphemtry, ImageJ); stimulation with ACEA (30 M), AM251
(1 M) or both for 1-day. n D 9–22 skin sections/group. (C) Representative images of K16 immuno-
histochemistry with organ cultured human skin samples with ACEA (1-day). (D) Quantitative K16
immunohistomorphometry within the epidermis of organ-cultured human skin samples after 1-day
of stimulation with ACEA .30 M/. n D 4 skin sections/group. Data are expressed as mean C SEM.
*p < 0:05, **p < 0:01.
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 7/18Figure 2 The CB1 speciﬁc agonist, ACEA signiﬁcantly inhibits K6 expression in cultured HaCaT
cells. (A) Representative images of K6 immunoﬂuorescence of cultured HaCaT KCs with ACEA .1 M),
AM251 (100 nM) or both for 1-day. (B) Statistical analysis of K6 immunoﬂuorescence intensity of
cultured HaCaT cells. n D 6 colonies/group (C) Statistical analysis of K6 gene expression in HaCaT cells
treated with vehicle control or ACEA .1 M/ for 8 h. Data are expressed as mean C SEM. *p < 0:05;
**p < 0:01; ***p < 0:001.
are known to express functional CB1 and CB2 (Leonti et al., 2010; Maccarrone et al., 2003;
Paradisi et al., 2008), and this had been conﬁrmed previously by our group, both on the
gene (RT-PCR analysis) and protein levels (immunocytochemistry and western blotting
techniques) (Toth et al., 2011). Thus, being a direct target of CB1-mediated signaling,
this makes these KCs not only an instructive cell culture tool for evaluating the direct,
dermis-independentroleofCB1-mediatedsignalingintheregulationofkeratinexpression
inhumanKCs,butmayalsoprovideﬁrstindicationsastohowtheobservedK6expression
couldrelatetowoundhealingand/orpsoriasis.
In accordance with our human skin organ culture results, ACEA (1 M) signiﬁcantly
down-regulated K6 staining intensity of HaCaT cells in vitro (Figs. 2A and 2B). This was
abrogated by the co-administration of the selective CB1 antagonist, AM251 (100 nM)
(Figs. 2A and 2B). Unexpectedly, though, AM251 alone had a partial inhibitory eVect on
K6 expression, although not signiﬁcant. This may be related to the fact that AM251 is an
inverse agonist (Dono & Currie, 2012; Fiori et al., 2011), and invites further study. The
inhibitory eVect of ACEA on K6 protein expression was further conﬁrmed by quantitative
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 8/18Figure 3 The CB1 speciﬁc agonist, ACEA signiﬁcantly decreases human epidermal keratinocyte pro-
liferation in situ. (A) Representative images of K6 (green) and Ki67 (red) double-immunoﬂuorescence
with organ cultured human skin treated with ACEA/AM251 (1-day). (B) Quantitative analysis of the
percentage of Ki67C KCs within organ cultured human epidermis. *p < 0:05; ***p < 0:001. n D 5–12
skin sections/group.
RT-PCR (Fig. 2C). Therefore, while HaCaT cells may exhibit relatively low CB expression
levels,atleastunderourassayconditions,theyshowedavigorousresponsetoCBligands.
The CB1 speciﬁc agonist, ACEA signiﬁcantly decreases human
epidermal keratinocyte proliferation in situ
However, the observed eVects of CB1-mediated signaling on epidermal K6 expression
could simply reﬂect the appreciated anti-proliferative eVects of CB1 agonists (Casanova et
al., 2003; Hermanson & Marnett, 2011; Toth et al., 2011). Moreover, K6 is overexpressed
in hyper-proliferative and wounded KCs (Weiss, Eichner & Sun, 1984), and both K6
expressionandbasalKCproliferationareincreasedinpsoriaticepidermallesions(Donetti
et al., 2012; GriYths & Barker, 2007; Korver et al., 2006; Litvinov et al., 2011; Mommers
et al., 2000; Navarro, Casatorres & Jorcano, 1995). Therefore, we next assessed whether
CB1 stimulation by CB1 speciﬁc agonist, ACEA, could aVect human KC proliferation
in situ.
Just as we had seen before with the non-selective endocannabinoid, AEA (Toth et al.,
2011),theCB1-speciﬁcsyntheticagonist,ACEAindeedsigniﬁcantlydecreasedhumanepi-
dermal KC proliferation in situ. This eVect was abrogated by the CB1-speciﬁc antagonist,
AM251(assessedbyquantitativeKi-67immunomorphometry,Figs.3Aand3B).
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pression in suprabasal cells in a proliferation-independent manner
Therefore, it needed to be dissected whether or not CB1 also reduces K6 expression in a
proliferation-independentmanner.ThiswasdonebyselectivelyassessingK6expressionin
non-proliferative (i.e. Ki-67-negative) epidermal KCs in situ. We found that K6 IR within
non-proliferative epidermis was also reduced by ACEA (Figs. 4A and 4B). Furthermore,
K6-expressing cells in the epidermis co-expressed CB1 in situ (Fig. 4C), suggesting a
direct eVect of CB1-agnosits on K6-expressing human epidermal KCs in situ. Thus, CB1
stimulation may aVect K6 expression both, by reducing KC proliferation and by down-
regulatingK6expressiondirectlyviaCB1inaproliferation-independentmanner.
Here we provide the ﬁrst evidence that CB1-mediated signaling directly regulates
K6/16 expression within normal human skin. Speciﬁcally, we show that CB1 stimulation
down-regulates expression of the hyper-proliferation-associated human keratins K6 in
vitroandin situ,andinhibitshumanepidermalKCproliferationin situ.
TheeVectofCB-mediatedsignalinginhumanKCbiologyremainstobefullyexplored.
As we have also observed in isolated human skin (Fig. 4C), CB1 protein expression is
detected mainly above the basal layer of the epidermis (Stander et al., 2005), i.e. above the
compartment where KC proliferation normally occurs most prominently. Wilkinson and
Williamson reported thatthe non-selective CB agonistHU210 inhibited KC proliferation.
However, this could not be blocked by either CB1 or CB2 antagonists, suggesting
that cannabinoids may also inhibit human KC proliferation through a non-CB1/CB2
mechanism (Wilkinson & Williamson, 2007). Nevertheless, it has been previously shown
that AEA, which can interact with CB1 on human KC (Biro et al., 2009), inhibited human
KCproliferationin situandin vitro(Tothetal.,2011).
Therefore, it was important to clarify whether speciﬁc CB1 stimulation inhibits human
epidermal KC proliferation in situ. By using CB1-speciﬁc agonists and antagonists we
clearly demonstrate that exclusive CB1 stimulation inhibited KC proliferation. Thus, CB1
is an important key regulator of human KC proliferation. Given the role of epidermal
hyperproliferationinthepathobiologyofpsoriasis(Donettietal.,2012;GriYths&Barker,
2007; Korver et al., 2006; Litvinov et al., 2011; Mommers et al., 2000; Navarro, Casatorres &
Jorcano, 1995), cannabimimetic agents that activate CB1, therefore, deserve consideration
asanovelpharmacologicalstrategyfortreatingpsoriasis.
Furthermore, increased numbers of activated mast cells are often observed in and
around lesional psoriatic skin, and increasing evidence suggests that mast cells are
functionally important key immunocytes in the pathogenesis of psoriasis (Carvalho,
Nilsson & Harvima, 2010; Namazi, 2005; Radosa et al., 2011; Suttle et al., 2012; Toruniowa
& Jablonska, 1988). Recently, we have shown that CB1 activation limits excessive mast cell
activity and even inhibits mast cell maturation of resident, intracutaneous progenitors
(Sugawara et al., 2012). Therefore, besides their anti-proliferative eVects on human
epidermal KCs, the anti-inﬂammatory (Richardson, Kilo & Hargreaves, 1998) and mast
cell-inhibitory properties of CB1 agonists in human skin (Sugawara et al., 2012) make
themaparticularlyattractiveclassofagentsinfuturepsoriasismanagement.
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 10/18Figure 4 The CB1 speciﬁc agonist, ACEA, signiﬁcantly decreases K6 expression in suprabasal cells
in a proliferation-independent manner. (A) Representative images of K6 (green) and Ki-67 (red)
double immunoﬂuorescence. Dotted rectangles indicate the reference area for quantitative immunohis-
tomorphometry of K6 ﬂuorescence intensity. (B) Quantitative analysis of K6 ﬂuorescence intensity in
non-proliferating(i.e.Ki67-negative)cellswithinhumanepidermisinsitu.DataareexpressedasmeanC
SEM.*p<0:05.nD5–7skinsections/group.(C)K6(green)andCB1(red)double-immunoﬂuorescence
study. Yellow arrows denote double-positive KCs.
Itshouldbenoted,thattheconstitutivelevelofK6expressioninorgan-culturedhuman
skin fragments is considerably higher than normal scalp skin in vivo. Presumably, this
occurs as a response to tissue dissection and organ culture, which is well-known to elicit
an immediate wound healing response in the epithelium. The latter rapidly starts to
migrate over the wound edge in an attempt to enwrap the exposed skin mesenchyme
Ramot et al. (2013), PeerJ, DOI 10.7717/peerj.40 11/18(epiboly phenomenon Stenn, 1981; Brown et al., 1991). This constitutive up-regulation
of K6 in organ-cultured normal human skin may greatly heighten the sensitivity to K6
expression-modulatory compounds, such as CB ligands, thus making human skin organ
culture a particularly sensitive and instructive tool for clinically relevant keratin research.
At the same time, however, caution is advised in extrapolating from these observation
madeinwhatessentiallyreﬂectsawoundhealingmilieutohealthy,unmanipulatedhuman
skinin vivo.
The current ﬁndings invite the speculation that the therapeutic down-modulation of
K6 and/or K16 expression by CB1 agonists and other cannabimimetics might become
exploitable for the management of other dermatoses besides psoriasis, for example
pachyonychia congenita (Hickerson et al., 2011; Zhao et al., 2011) and acne (Biro et al.,
2009), and could be used to modulate KC migration-dependent reepithelialization in
wound healing, similar to related ﬁndings in periodontal and intestinal wound repair
(Kozonoetal.,2010;Wrightetal.,2005).
CONCLUSION
Our results suggest that cannabinoids and their receptors constitute a novel, clinically
relevant control element of human K6 and K16 expression. Therefore, cannabimimetic
agents might be relevant for the treatment of several skin conditions related to aberrant
K6/K16 expression, such as psoriasis and wound healing. In addition, skin organ culture
is shown to be a clinically and physiologically relevant model system for investigating the
eVectofCB1speciﬁcagonists/antagonistsonhumanskin.
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